Amicus Therapeutics is a biopharmaceutical company that was founded in 2002 and is based in Cranbury, New Jersey. It is at the forefront of treating rare and dangerous orphan diseases through advanced therapies and offers a spread of possible treatments for many different human genetic diseases. Their top product, which is a personalized medicine named migalastat is in the last stages of development and is aimed to treat people with Fabry disease. SD-101 is another product in the later stages of development, which is designed to be therapeutic for people who suffer from the rare genetic connective tissue disorder known as Epidermolysis Bullosa (EB).
An Advocate For Patients
Amicus Therapeutics also advocates for patients by collaborating with individual patients, patient organizations, healthcare practitioners, and caregivers. Acting as a middleman between patients, their families, and the resources they need, Amicus believes in creating initiatives that help with the suffering that rare conditions can cause. Their commitment to the people they help treat and the families that care for them is huge, and their dedication and passion for healing people in need shines through everything they do (GoogleFinance). By searching for better therapies that can people and learning from individual cases the company is changing the way that biopharmaceutical companies see people.
Integrity and Ethics
Amicus Therapeutics is proud of its work ethic and integrity, and CEO John F. Crowley has made statements that ensure the public that his company approaches to medicine and the decisions they make as if they or a close family member was suffering from the disease or condition in question (https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo). This particular fact sets them apart from all of the other biopharmaceutical companies in existence because many of them are focused on how much money they can make rather than how many people they can help. In a show of confidence and faith in the company, The Michael J. Fox Foundation donated $500,000, in 2010, to support studies that were being done by Amicus and the company also received a $210,000 grant from the Alzheimer’s Drug Discovery Foundation.
While based in New Jersey, Amicus Therapeutics has offices around the world including locations in the United Kingdom, Spain, Germany, Italy, France, and the Netherlands.